- Defence Therapeutics (DTC) has announced a breakthrough in its pre-clinical research program on its AccuTOX molecules
- Defence’s scientific team recently identified a novel function for the use of “free” Accum and its recently developed variants as anti-cancer molecules
- Defence’s scientific team discovered that the AccumTM moiety behaves as a toxic “bullet” to cancer cells
- Accum variants are being tested for their effectiveness against breast, colon, melanoma and lymphoma cancers
- The company is developing an “intelligent” Poly-AccuTOX molecule capable of selectively killing a wide range of cancer cells without collateral side effects
- The Global Immunotherapy Market size is expected to reach US$117 billion by 2026
- Defence Therapeutics is a biotechnology company focused on engineering vaccines and ADC products using its proprietary platform
- Defence Therapeutics Inc. (DTC) opened trading at C$7.50 per share
Defence Therapeutics (DTC) has announced a breakthrough in its pre-clinical research program on its AccuTOX molecules as potent anti-cancer agents.
The AccumTM technology platform enhances intracellular delivery of proteins of pharmacological interests such as ADCs or vaccine antigens. Defence’s scientific team recently identified a novel function for the use of “free” Accum and its recently developed variants as anti-cancer molecules.
“The Accum technology platform is displaying multiple targets in its versatility. You can use it with antibody drug conjugates (ADC) or any other protein of interest such as vaccine antigens to enhance their intracellular delivery to target cells. We additionally discovered that when delivered without direct linking onto protein, the AccumTM moiety behaves as a toxic “bullet” to cancer cells. Such discovery re-enforces the idea that AccumTM can be exploited for various applications without the need to develop other unrelated molecules,” said Sebastien Plouffe, CEO of Defence Therapeutics.
The Defence team has engineered more than 50 Accum variants. They are currently being testing for their therapeutic efficacy against breast, colon, melanoma and lymphoma cancers.
In addition, a new strategy is currently being developed to engineer an “intelligent” Poly-AccuTOX molecule capable of selectively killing a wide range of cancer cells without collateral side effects.
Global Immunotherapy Market size to reach US$117 billion by 2026 according to Market Study Report LLC.
Defence Therapeutics is a biotechnology company focused on engineering vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics’ platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
Defence Therapeutics Inc. (DTC) opened trading at C$7.50 per share.